Literature DB >> 3529320

beta-Lactam antibiotics: structural relationships affecting in vitro activity and pharmacologic properties.

H C Neu.   

Abstract

The essential nucleus of beta-lactam antibiotics is the four-membered ring, which can exist fused to form bicyclic ring structures or with moieties alone affixed to the four atoms. Penicillins, penems, carbapenems, and clavams have asymmetric centers at C-5 and C-6; cephalosporins and oxacephems have asymmetric centers at C-6 and C-7. Penicillins, cephalosporins, and monobactams require a beta-acylamino group for antimicrobial activity. Cephalosporins can undergo modification at C-3 and C-7 in both the alpha and beta position. Sulfur can be replaced with oxygen to achieve a more reactive nucleus. The most useful 7-beta-acylamino groups have been a 2-aminothiazolyl and an iminomethoxy or carboxypropyl group. Substitutions on the 7-alpha position increase beta-lactamase stability but decrease activity against staphylococci and Streptococcus pneumoniae. C-3 substitutions, particularly pyridinium groups, increase activity against Pseudomonas aeruginosa and Staphylococcus aureus. Carbapenems possess 6-alkyl substitutions in a trans configuration and inhibit aerobic, anaerobic gram-positive, and gram-negative bacteria. Monobactams are activated by sulfonic, phosphoric, or carboxyl groups, and their properties are related to the C-3-acyl side chain and their beta-lactamase stability to the C-4 grouping. beta-Lactamase inhibitors acylated by beta-lactamases can be penicillanic acid derivatives or clavulanates.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3529320     DOI: 10.1093/clinids/8.supplement_3.s237

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  16 in total

Review 1.  Drug allergy in cystic fibrosis.

Authors:  R B Moss
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 2.  Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.

Authors:  George G Zhanel; Alyssa R Golden; Sheryl Zelenitsky; Karyn Wiebe; Courtney K Lawrence; Heather J Adam; Temilolu Idowu; Ronald Domalaon; Frank Schweizer; Michael A Zhanel; Philippe R S Lagacé-Wiens; Andrew J Walkty; Ayman Noreddin; Joseph P Lynch Iii; James A Karlowsky
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

Review 3.  The future of new oral antibiotics including the quinolones.

Authors:  M G Bergeron
Journal:  CMAJ       Date:  1988-01-01       Impact factor: 8.262

Review 4.  The development of beta-lactam antibiotics in response to the evolution of beta-lactamases.

Authors:  S Y Essack
Journal:  Pharm Res       Date:  2001-10       Impact factor: 4.200

Review 5.  Cephalosporins in the treatment of meningitis.

Authors:  H C Neu
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 6.  Cephalosporins--cefotaxime 10 years later, a major drug with continued use.

Authors:  H C Neu
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 7.  Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.

Authors:  George G Zhanel; Christopher D Lawson; Heather Adam; Frank Schweizer; Sheryl Zelenitsky; Philippe R S Lagacé-Wiens; Andrew Denisuik; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2013-02       Impact factor: 9.546

8.  Comparative in vitro activity and beta-lactamase stability of RU29246, the active metabolite of HR916B.

Authors:  K W Yu; N X Chin; H C Neu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-07       Impact factor: 3.267

9.  Susceptibility to beta-lactam antibiotics in septicemia isolates from twenty-nine European laboratories. European Study Group on Antibiotic Resistance.

Authors: 
Journal:  Eur J Clin Microbiol       Date:  1987-10       Impact factor: 3.267

10.  In vitro and in vivo activities of SCE-2787, a new parenteral cephalosporin with a broad antibacterial spectrum.

Authors:  T Iwahi; K Okonogi; T Yamazaki; S Shiki; M Kondo; A Miyake; A Imada
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.